en Adults Hematology & Oncology Adults Hematology & Oncology متا آنالیز Meta-analysis <div style="text-align: justify;"><span style="line-height:2;"><span style="font-family:Times New Roman;"><span style="font-size:14px;"><strong>Background:</strong> Stem-like CD8+ T cells, marked by TCF1 and PD-1, possess self-renewal and effector differentiation abilities, crucial for cancer immunotherapy. Despite tumor microenvironment constraints, their abundance often correlates with favourable outcomes.<br> <strong>Aim: </strong>To assess the prognostic and predictive relevance of stem-like CD8+ T cells in patients receiving immunotherapy for cancer.<br> <strong>Methodology:</strong> 721 publications from PubMed, Embase, Scopus, and Web of Science (2015&ndash;2025) were evaluated in accordance with PRISMA 2020 guidelines. 8 studies were included in the meta-analysis. Two independent reviewers conducted data extraction. Pooled hazard ratios (HRs) and confidence intervals (CIs) were calculated using RevMan software, and the I2 statistic was employed to measure heterogeneity. The ROBINS-I instruments and the Newcastle-Ottawa Scale were used to assess the quality of the study.<br> <strong>Results: </strong>8 of the 13 included papers qualified for meta-analysis. Follow-up periods varied from six months to five years, and sample sizes ranged from 12 to 94 patients. Multiplex immunofluorescence, scRNA-seq, or flow cytometry were used to quantify stem-like CD8+ T cells. Hazard ratios (HRs) in the woodland plot ranged from 1.18 to 28.50. High HRs of 4.31 (95% CI: 2.68&ndash;6.92) and 28.50 (95% CI: 3.30&ndash;246.15) were observed in two investigations, suggesting a significant adverse prognostic effect. With considerable heterogeneity (I2 = 89%, Chi2 = 61.38, P < 0.00001), the pooled HR was 1.34 (95% CI: 1.22&ndash;1.47).<br> <strong>Conclusion: </strong>In cancer immunotherapy, stem-like CD8+ T cells serve as both therapeutic targets and significant prognostic indicators. Standardized methods for evaluation and strategies to lessen immunosuppressive effects in the tumor microenvironment are necessary for clinical use.</span></span></span></div> Cancer Immunotherapy, CD8 Positive T Lymphocytes, Immunologic Surveillance, Stem Cells, T Cell Exhaustion 69 81 http://ijbc.ir/browse.php?a_code=A-10-2116-1&slc_lang=en&sid=1 Sonika Sharma soniyasharma19922@gmail.com 100319475328460012877 100319475328460012877 Yes Department of Anatomy, Teerthanker Mahaveer Medical College & Research Centre, Teerthanker Mahaveer University, Moradabad, Uttar Pradesh, India. Prithpal Singh Matreja 100319475328460012878 100319475328460012878 No Department of Pharmacology, Teerthanker Mahaveer Medical College & Research Centre, Teerthanker Mahaveer University, Moradabad, Uttar Pradesh, India. Sudhir Singh 100319475328460012879 100319475328460012879 No Department of Microbiology, Teerthanker Mahaveer Medical College & Research Centre, Teerthanker Mahaveer University, Moradabad, Uttar Pradesh, India. Pothu Usha Kiran 100319475328460012880 100319475328460012880 No Department of Biochemistry, Teerthanker Mahaveer Medical College & Research Centre, Teerthanker Mahaveer University, Moradabad, Uttar Pradesh, India.